Assynt House, Beechwood Park Inverness, IV2 3BW Telephone: 01463 717123

www.nhshighland.scot.nhs.uk



NHS HIGHLAND CLINICAL GOVERNANCE COMMITTEE

7 March 2024 at 9.00am Virtual Meeting Format (Microsoft Teams)

- All cameras should be turned on
- Use raise hand facility to discuss items do not use MS Teams chat

Distribution: 28 February 2024

AGENDA

Time	1.	Standing Items	
09.00-09.10 1.		Welcome and Apologies	
	1.2	Declarations of Interest Members are asked to consider whether they have an interest to declare in relation to any item on the agenda for this meeting. Any Member making a declaration of interest should indicate whether it is financial or non-financial and include some information on its nature. Advice may be sought from the Board Secretary's Office prior to the meeting taking place.	
	1.3	Minute of Previous meeting Thursday, 18 January 2024, Rolling Action Plan and Committee Workplan 2023/2024 The Committee is asked to Approve the Minute of the meeting of 18 January 2024, Consider actions arising therefrom and Note the updated rolling action plan and Committee Work Plan.	PP.1-18
09.10-09.20	1.4	Matters Arising SCI Gateway Referral Update C Copeland, Deputy Medical Director Members are advised that an update will come to the next meeting.	
	2.	Service Updates	
09.20-9.40		2.1 NDAS Service Update Report by Tracey Gervaise, Head of Operations (Woman and Child) The Committee is asked to Note the report and accept Limited assurance.	PP.19-43
	3.	Emerging Issues/Executive and Professional Leads Reports by Exception	
9.40-9.50			PP.242- 246

	4.	Patient Experience and Foodback	
9.50-10.00	4.	Patient Experience and Feedback Report by Leah Smith, Complaints Manager	PP.44-48
3.50-10.00		Report by Lean Smith, Complaints Manager	11.44-40
		The Committee is asked to Note the report and accept Moderate assurance.	
	5.	Clinical Governance Quality and Performance Data	PP.229-
40.00.40.45		Demant his Minian Manniago on habelf of Devid Detana Decard Madical Director	241
10.00-10.15		Report by Mirian Morrison on behalf of Boyd Peters, Board Medical Director	
		The Committee is asked to Note the report and accept Moderate assurance.	
5.1		IQR – Spotlight on Cancer	PP.122-
		Report by Leah Smith, Complaints Manager	128
		The Committee is asked to Note the report and accept Moderate assurance.	
		Annual Delivery Dien	
10.15-10.30	6.	Annual Delivery Plan	
10.13-10.30		Members are advised that all programmes are presently under review. A	
		spotlight on Cancer Complaints and Performance has been provided under Item 5	
		on the agenda.	
	7.	Operational Unit Reports by Exception and Emerging Issues with Minutes	
		from Patient Quality and Safety Groups/Argyll and Bute Clinical and Care Governance Group	
10.30-11.00	7.1	Argyll and Bute HHSCP	PP.49-69
10.00 11.00	, , ,		
		The Committee is asked to Note the report and accept Moderate assurance.	
	7.2	Highland HSCP	PP.129- 147
		The Committee is asked to Note the report and accept Moderate assurance.	141
		The Committee is asked to Note the report and accept Moderate assurance.	
	7.3	Acute Services	PP.70-77
		The Committee is asked to Note the circulated report and associated Minute and	
		accept Moderate assurance.	
	7.4	Infants Children and Young People's Clinical Governance Group (plus	PP.78-89
		Minute of Meeting held on 12 January 2024)	
		, ,	
		The Committee is asked to Note the circulated report and associated Minute and	
		accept Moderate assurance.	
		Comfort Break	
		Communication of the contraction	
	8.	Infection Prevention and Control Report	
11.00-11.10		Report by Catherine Stokoe, Infection Control Manager	PP.90-
		The Committee is solved to Nietz the contents of the new of the second and account B	101
		The Committee is asked to Note the contents of the report and accept Moderate assurance.	
		assurance.	
	9.	Six Monthly Exception Reports	
11.10-11.20	9.1	Area Drugs and Therapeutics Committee	PP.102-
		Report by Sarah Buchan, Director of Pharmacy and Controlled Drugs	114
		The Committee is asked to Note the contents of the report and accept Madarate	
		The Committee is asked to Note the contents of the report and accept Moderate assurance.	
		assarance.	
	9.2		PP.148-
		Report by Boyd Peters, Board Medical Director	151

		The Committee is solved to:		
		The Committee is asked to:		
		(a) Accept moderate assurance,		
	(b) Note the content of the report			
		(c) That the risk noted be appropriately modified and added to the risk register(d) Consider if further work is required to develop the noted risk so it is		
		appropriately linked to relevant risk in the level two and level three		
		registers.		
	9.3	Scottish Patient Safety Programme		
		Report by Mirian Morrison, Clinical Governance Manager		
		Members are advised that an update will come to the next meeting.		
		Members are advised that air apaate will come to the next meeting.		
	10.	Public Health		
11.20-11.30	10.1	Vaccination Update		
		Presentation by Tim Allison, Director of Public Health and Policy		
	11.	Committee Function and Administration		
11.30-11.45	11.1	Committee Annual Report 2023/2024	PP.115-	
		Report by Alasdair Christie, Committee Chair	119	
		The Committee is asked to Endorse the Clinical Governance Committee Annual		
		Report 2023-24.		
		Nopoli 2020 2 II		
	11.2		PP.120-	
		Report by Alasdair Christie, Committee Chair	121	
		The Committee is asked to note and agree the Workplan for 2024-25.		
		The Committee is asked to note and agree the Workplan for 2024-25.		
	12.	Clinical Advisory Group Process Review	PP.152- 228	
		Report by Paul Nairn on behalf of Boyd Peters, Medical Director		
			220	
		The Committee is asked to:	220	
			220	
		(a) note the content of the report.	220	
			220	
		 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and 	220	
		(a) note the content of the report.(b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and	220	
	13.	 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 	220	
11.45-11.50	13.	 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and 	220	
11.45-11.50	13.	 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 2024 Meeting Schedule The Committee is asked to Note the remaining meeting schedule for 2024:	220	
11.45-11.50	13.	 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 2024 Meeting Schedule The Committee is asked to Note the remaining meeting schedule for 2024: 9 May 2024	220	
11.45-11.50	13.	 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 2024 Meeting Schedule The Committee is asked to Note the remaining meeting schedule for 2024: 9 May 2024 11 July 2024 	220	
11.45-11.50	13.	 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 2024 Meeting Schedule The Committee is asked to Note the remaining meeting schedule for 2024: 9 May 2024	220	
11.45-11.50	13.	 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 2024 Meeting Schedule The Committee is asked to Note the remaining meeting schedule for 2024: 9 May 2024 11 July 2024 5 September 2024 	220	
11.45-11.50	13.	 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 2024 Meeting Schedule The Committee is asked to Note the remaining meeting schedule for 2024: 9 May 2024 11 July 2024 5 September 2024 7 November 2024 Reporting to the NHS Board 	220	
		 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 2024 Meeting Schedule The Committee is asked to Note the remaining meeting schedule for 2024: 9 May 2024 11 July 2024 5 September 2024 7 November 2024 Reporting to the NHS Board Matters being identified for escalation should trailed by relevant Executives under 	220	
		 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 2024 Meeting Schedule The Committee is asked to Note the remaining meeting schedule for 2024: 9 May 2024 11 July 2024 5 September 2024 7 November 2024 Reporting to the NHS Board 	220	
		 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 2024 Meeting Schedule The Committee is asked to Note the remaining meeting schedule for 2024: 9 May 2024 11 July 2024 5 September 2024 7 November 2024 Reporting to the NHS Board Matters being identified for escalation should trailed by relevant Executives under Item 5 on the agenda. 	220	
		 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 2024 Meeting Schedule The Committee is asked to Note the remaining meeting schedule for 2024: 9 May 2024 11 July 2024 5 September 2024 7 November 2024 Reporting to the NHS Board Matters being identified for escalation should trailed by relevant Executives under 	220	
11.50-11.55	14.	 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 2024 Meeting Schedule The Committee is asked to Note the remaining meeting schedule for 2024: 9 May 2024 11 July 2024 5 September 2024 7 November 2024 Reporting to the NHS Board Matters being identified for escalation should trailed by relevant Executives under Item 5 on the agenda. The Committee is asked to Consider and Identify any matters requiring escalation to the NHS Board for consideration. 	220	
		 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 2024 Meeting Schedule The Committee is asked to Note the remaining meeting schedule for 2024: 9 May 2024 11 July 2024 5 September 2024 Reporting to the NHS Board Matters being identified for escalation should trailed by relevant Executives under Item 5 on the agenda. The Committee is asked to Consider and Identify any matters requiring escalation 	220	
11.50-11.55	14.	 (a) note the content of the report. (b) approve the completion of the Internal Audit review and implementation of the recommendations of the Clinical Advisory Group process and governance recommendations and (c) take moderate assurance. 2024 Meeting Schedule The Committee is asked to Note the remaining meeting schedule for 2024: 9 May 2024 11 July 2024 5 September 2024 7 November 2024 Reporting to the NHS Board Matters being identified for escalation should trailed by relevant Executives under Item 5 on the agenda. The Committee is asked to Consider and Identify any matters requiring escalation to the NHS Board for consideration. 	220	

	Clinical Governance Committee Membership		
Non-Executive Members (4x)	Chair	Alasdair Christie	
	Member	Dr Gaener Rodger	
	Member	Joanne McCoy	
	Member	Muriel Cockburn	
Area Clinical Forum Chair	Member	Catriona Sinclair	
Staffside Representative	Member	Elspeth Caithness	
Independent Public Members (2x)	Member	Liz Henderson	
	Member	VACANT	
Board Medical Director	Member/Lead Officer	Dr Boyd Peters	
Director of Public Health	Member	Tim Allison	
Board Nurse Director	Member	Louise Bussell	
Ex Officio	Board Chair	Sarah Compton-Bishop	
	Board Chief Executive	Pamela Dudek	
In attendance (Routinely Invited)	Deputy Medical Directors	C Copeland	
	Chief Officer (North)/Director of	Pamela Cremin	
	Community Services		
	Chief Officer (Argyll and Bute)	Evan Beswick	
	Chief Officer (Acute)	Katherine Sutton	
	Clinical Director of eHealth/Head of eHealth (Substitute)	Iain Ross	
	Director of Pharmacy	Sarah Buchan	
	Board Clinical Governance Manager	Mirian Morrison	
	Clinical Governance Manager (Argyll and Bute)	Margo Howatson	
	Contracted Services Representative (Highland Council)	Jane Park	
	Associate Director (Allied Health Professionals)	Jo McBain	
	Deputy Nurse Director	Kate Patience-Quate	
	Associate Nurse Directors		
	Head of Midwifery	Isla Barton	
	Director of Adult Social Care	Simon Steer	
	Consultant Community Paediatrician	Stephanie Govenden	
	Lead for Realistic Medicine	Kate Arrow	